DNA TOPOISOMERASE-I AND TOPOISOMERASE-II IN CANCER-CHEMOTHERAPY - UPDATE AND PERSPECTIVES
DNA TOPOISOMERASE-I AND TOPOISOMERASE-II IN CANCER-CHEMOTHERAPY - UPDATE AND PERSPECTIVES
复制标题
DOI：
10.1007/bf00685611
复制
发表时间：
1993-05-01
影响因子：
3
通讯作者：
POMMIER, Y
中科院分区：
文献类型：
--
作者：
POMMIER, Y
DNA分子的极大长度以及DNA与真核细胞核中结构基质的结构附着是导致发生在DNA代谢(复制、转录、修复重组、有丝分裂等)过程中的Watson-Crick双螺旋链分离相关的拓扑约束的原因。DNA拓扑异构酶是一种核酶，通过使DNA瞬间断裂来调节DNA的拓扑结构。哺乳动物DNA拓扑异构酶有两种类型：拓扑异构酶I和II[57，93，94]。虽然DNA拓扑异构酶II抑制剂已被公认为抗癌药物[57，67]，但拓扑异构酶I抑制剂目前正在进行I期试验(综述见[67，74])。
The extreme length of DNA molecules as well as the structural attachment of the DNA to a structural matrix in the nuclei of eukaryotic cells are responsible for the topological constraints associated with strand separation of the Watson-Crick double-helix, which takes place during DNA metabolism (replication, transcription, repair recombination, mitosis...). DNA topoisomerases are nuclear enzymes that modulate the topological structure of DNA by making transient DNA breaks. There are two types of mammalian DNA topoisomerases: topoisomerases I and II [57, 93, 94]. Whereas DNA topoisomerase II inhibitors are well established as anticancer agents [57, 67], topoisomerase I inhibitors are presently undergoing phase I trial (for review see [67, 74]).